ABSTRACT
For the characteristics of high stability， high conservation between species， and tissue specificity， circular RNA(circRNA) has been expected to become a new molecular biomarker for the clinical diagnosis， treatment and prognosis， and the potential target for targeted therapy. Study on the traditional Chinese medicine(TCM) syndrome includes not only the macro indexes collected by using four traditional methods of diagnosis， but also contains some micro information that can not be achieved by using the four traditional diagnosis methods. The questions such as how to deal with the relationship between the holistic concept of TCM and micro research， and how to solve the contradiction between the fuzziness of syndrome description and the accuracy of microscopic research， need to be considered before the micro research in TCM syndrome. circRNA as a new field of understanding human disease， may provide some ideas for the TCM syndrome research due to its characteristics. Overall， it is necessary to pay attention to explore the molecular level with same syndrome in different diseases and reveal the connotation and essence of syndromes by understanding of circRNA.
Subject(s)
Humans , Biomarkers , Biomedical Research , Medicine, Chinese Traditional , RNA , Genetics , SyndromeABSTRACT
To analyze the medication characteristics and compatibility rules in treatment of Qi stagnation and blood stasis syndrome. Chinese patent medicine prescriptions for Qi stagnation and blood stasis were collected from the 2015 edition of Pharmacopoeia of the people's Republic of China(herein after referred to as Chinese Pharmacopoeia) and Drug Standards of the People's Republic of China Ministry of Public Health-Chinese Patent Drug(herein after referred to as Chinese Patent Drug). Traditional Chinese medicine inheritance support system(TCMISS V2.5) was used to analyze the rules of prescription composition. Seventy-nine prescriptions included 105 symptoms, and dysmenorrhea, palpitations, chest tightness, stomach pain were common symptoms of Qi stagnation and blood stasis syndrome. Among 221 herbs, Chuanxiong Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma and Angelicae Sinenses Radix ranked top 3 in usage frequency for the treatment of Qi stagnation and blood stasis. The herbal combinations included Angelicae Sinenses Radix-Chuanxiong Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma-Carthami Flos, Chuanxiong Rhizoma-Carthami Flos, and Carthami Flos-Chuanxiong Rhizoma-Paeoniae Radix Rubra-Salviae Miltiorrhizae Radix et Rhizoma-Angelicae Sinenses Radix-Cyperi Rhizoma-Corydalis Rhizoma was the core herbal combination. In addition, a new prescription(Foenoculi Fructus-Alpiniae Officinarum Rhizoma-Caryophylli Flos-Angelicae Sinenses Radix-Chuanxiong Rhizoma-Leonuri Herba) for Qi stagnation and blood stasis syndrome was formed. Overall, the main symptom for the Qi stagnation and blood stasis syndrome could be pain, but because of different pathogenic factors, it could be reflected by different symptoms. Accordingly, invigorating the circulation of Qi and blood is the basic treatment for the Qi stagnation and blood stasis. Meanwhile, the treatment based on differentiation of symptoms and signs for different reasons should be considered. The prescriptions mainly included the herbs that could invigorate the circulation of Qi and blood, and were accompanied by the herbs that could warm spleen and stomach for dispelling cold.
ABSTRACT
Coronary heart disease(CHD) has become a major public health problem in the world, while the unstable angina (UA) is one of an important type. Hypofunction of yang qi in chest and cardiac blood stasis has been considered as the basic pathogenesis of UA.According to the deficiency of yang and blood stasis run through the process of CHD, fu yang and activating blood circulation could be main treatment. Wenxin decoction which has the function of fu yang and activating blood circulation, not only can effectively improve the symptoms of angina pectoris, the ischemic ECG, but also can significantly improve blood rheology, blood lipids and so on. So deepening the theory of ″fu yang and activating blood circulation″ and the application of ″Wenxin decoction″ in the treatment of UA would have an important clinical value for improving the therapeutic efficacy of CHD.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effect of dihydroartemisinin (DHA) on the BCR/ABL fusion gene in leukemia K562 cell.</p><p><b>METHODS</b>K562 cells were cultured in vitro. The rate of proliferation inhibition of cells treated with various concentrations of DHA were determined by using [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) method. Expression of BCR/ABL fusion gene was analyzed by reverse transcription(RT-PCR) before and after DHA treatment. Apoptosis of K562 cells was detected by flow cytometry.</p><p><b>RESULTS</b>The growth of K562 cells was inhibited when the concentrations of DHA were 10-160 umol/L. With the added dose of DHA, the growth inhibition was remarkable, with the rate of inhibition risen from 52.76% to 94.65%. The expression of BCR/ABL fusion gene, as detected by RT-PCR after incubating the K562 cells with 20 umol/L DHA, measured as ΔCt = 4.45 ± 0.25 after 12 h and ΔCt = 5.23 ± 0.21 after 24 h, which was significantly lower compared with that of the control ( ΔCt = 4.23 ± 0.21, P < 0.05).</p><p><b>CONCLUSION</b>DHA can inhibit the proliferation of leukemia K562 cells and facilitate the induction of apoptosis by downregulating the expression of BCR/ABL fusion gene.</p>
Subject(s)
Humans , Artemisinins , Pharmacology , Fusion Proteins, bcr-abl , Genetics , Gene Expression , Genes, abl , K562 Cells , Leukemia , Genetics , Tumor Cells, CulturedABSTRACT
The purpose of this study was to explore the clinical value of the platelet antibody screening and typing in platelets transfusion by using microcolumn gel immunoassay (MGIA). The platelets antigen-antibody reactions including the antibody screen and blood crossmatch were detected by MGIA. The results indicated that the detection of platelet antibody showed positive in 30 cases of aplastic anemia (AA), 11 cases of myelodysplastic syndrome (MDS), 24 out of 25 cases of leukemia and 1 out of cases of other diseases, while detection of platelet antibody showed negative in 20 normal volunteer donors. The number of platelet antibody crossmatch coincidence in 112 specimens of AA, 42 specimens of MDS and 95 specimens of leukemia were 45, 20 and 40, the coincidence rates were 40.18%, 47.62% and 42.11%. The mean corrected count increment (CCI) in 20 patients received platelet transfusion many times was 18.2 after crossmatch and 4.7 before crossmatch. It is concluded that the positive rate of platelet antibody screening is very high in patients with hematologic malignancies, the coincidence rate of platelet antibody crossmatch in 249 blood samples is between 40% and 48%, and the efficiency of using crossmatched platelets in clinic is enhanced significantly.